Today, CBD is available in various forms, including liquids, capsules, oils, creams, and even edibles such as lollipops and gummy bears.
Recognizing the rapid expansion of this industry, the FDA held a public hearing to gather scientific data and insights on products containing cannabis or cannabis-derived compounds. During this session, Acting FDA Commissioner Ned Sharpless acknowledged the regulatory challenges surrounding CBD and admitted that the agency still lacks comprehensive knowledge regarding its full health effects. Critical questions remain unanswered, including safe daily consumption levels, potential risks during pregnancy and childhood, and interactions with other medications. Despite these uncertainties, one fact is clear—the CBD market is growing, and discussions around its regulation continue to intensify.
Many businesses are eager to enter this emerging market. However, despite the enthusiasm, regulatory uncertainties and evolving scientific research make it a complex landscape to navigate—particularly for organizations with limited experience in the cannabis sector.
For companies considering entry into the CBD market, here are five critical questions to evaluate before moving forward:
- How do federal, state, and local regulations differ?
While the 2018 Farm Bill marked a significant step toward CBD legalization, federal regulations remain in flux. States have taken varying stances—some supportive, others restrictive. Additionally, local enforcement agencies may not always differentiate between hemp-derived CBD and marijuana products, creating potential legal complications. - How do regulations vary for different types of CBD products (e.g., ingestible vs. topical)?
Many assume CBD regulations align with state medical or recreational marijuana laws, but this is often not the case. THC levels play a crucial role in determining legality. Furthermore, different product categories—such as vape pens versus topicals—carry different levels of regulatory scrutiny and risk. - How will new research on CBD’s effectiveness impact businesses?
As scientific studies on CBD continue to emerge, businesses must closely monitor potential findings. Any research indicating health risks or safety concerns could significantly impact consumer confidence and regulatory policies. - How does CBD investment affect banking, investors, and financial relationships?
Given that marijuana remains a Schedule 1 substance under federal law, banking institutions face restrictions when handling funds associated with cannabis sales. This presents challenges for businesses legally selling marijuana products at the state level and can even complicate financial transactions for hemp-based CBD companies.